`Case 3:23-cv-04200-ZNQ-TJB Document 13-5 Filed 10/13/23 Page 1 of 2 PagelD: 790
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT C
`EXHIBIT C
`
`
`
`
`
`
`
`Case 3:23-cv-04200-ZNQ-TJB Document 13-5 Filed 10/13/23 Page 2 of 2 PageID: 791
`
`From: Pete Zorn <pete.zorn@genevant.com>
`Sent: Friday, June 3, 2022 11:53 AM
`To: Raymond Parker <Raymond.Parker@biontech.us>
`Cc: Bauer, Michael P <michael.P.bauer@pfizer.com>
`Subject: Memorializing Disclosure of Patents
`
`Ray:
`
`Thank you to you and Bruce for the call on Wednesday. We are sending this email to memorialize our disclosure made on
`that call of two additional Arbutus patents, U.S. Patent Nos. 11,298,320 and 11,318,098, which we believe, like the patents
`specified in our November 23, 2020 and October 12, 2021 letters sent to Pfizer and BioNTech, may be infringed by the
`manufacture, importation, offer for sale, sale, and/or use of the Pfizer‐BioNTech COVID‐19 vaccine Comirnaty.
`
`We look forward to speaking with you again soon.
`
`Pete Zorn
`President and Chief Legal Officer
`Genevant Sciences, Inc.
`245 Main Street, 2nd Floor
`Cambridge, MA 02142
`O: 1‐617‐500‐0764
`M: 1‐781‐941‐6290
`
`